Association Between Rheumatoid Arthritis and Pulmonary Hypertension: A Clinical Investigation
Abstract
Assessment of pulmonary hypertension (PAH) frequency and its association with interstitial lung disease (ILD), left ventricular diastolic dysfunction (LVDD), left ventricular systolic dysfunction (LVSD), and valvular heart diseases (VHD) in adult patients with rheumatoid arthritis (RA). Cross-sectional study. Cardiology and Rheumatology Departments, Ghaem Medical Center, Mashhad University of Medical Sciences, Mashhad, Iran. A total of 40 patients with RA without history or clinical features of cardiac diseases underwent cardiopulmonary and rheumatological assessment, including history taking, physical examination, chest X-ray, chest High-Resolution Computed Tomography (HRCT), and echocardiography. Echocardiographic variables of patients with RA were measured and analyzed. The relationship between rheumatoid arthritis and pulmonary hypertension. The prevalence of PAH was 60% in RA. The tests showed no significant differences in PAH between age and gender groups. The most common valve involvement among patients was tricuspid insufficiency, followed by mitral insufficiency. Grades I and II LVDD were present in 27.5% and 2.5% of patients, respectively. There were significant correlations between systolic velocity (Sm) and ejection fraction, early diastolic velocity and diastolic velocity, as well as Sm and systolic wave velocity. This study revealed a high prevalence of severe LVDD in RA patients with PAH. Early diagnosis and management of cardiovascular risk factors may prevent the development and progression of PAH in RA patients.
1. BANIK S, TAPADAR S, RAY A, CHAUDHURI A. A Study on Pulmonary Manifestations of Rheumatoid Arthritis. Journal of Clinical and Diagnostic Research 2018; 12(6):5–9.
2. Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe H. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int 2017; 114(12):197–203.
3. Hoeper M, Humbert M, Souza R, Idrees M, Kawut S, Sliwa-Hahnle, K et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4(4):306–322.
4. Goldman L, Ausiello D. Cecil medicine. Philadelphia: Saunders; 2008.
5. Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother 2017; 8(3):81–86.
6. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97(8):612–622.
7. Mazurek J, Forfia P. Enhancing the accuracy of echocardiography in the diagnosis of pulmonary arterial hypertension: looking at the heart to learn about the lungs. Curr Opin Pulm Med 2013; 19(5):437–445.
8. Augustine D, Coates-Bradshaw L, Willis J, Harkness A, Ring L, Grapsa J et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract 2018; 5(3):G11–G24.
9. Panagiotidou E, Sourla E, Kotoulas S, et al. Rheumatoid arthritis associated pulmonary hypertension: Clinical challenges reflecting the diversity of pathophysiology. Respir Med Case Rep 2017; 13(20):164–167.
10. Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81(9646–656).
11. Mankad R, Ball C, Myasoedova E, Matteson E. Non-atherosclerotic Cardiac Manifestations of Rheumatoid Arthritis, In: Semb AG editor. Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis, Switzerland, Springer International Publishing.; 2017.
12. Kim C, Cho E, Lee Y, Kim Y, Hah Y, Kim D. Disease-specific Proteins from Rheumatoid Arthritis Patients. J Korean Med Sci 2006; 21(3):478–484.
13. Mir A, Naghibzadeh M, Saadati N. INDEX: Incremental depth extension approach for protein–protein interaction networks alignment. BioSystems 2017; 162:24–34. doi:10.1016/j.biosystems.2017.08.005.
14. Sazvar M, Naghibzadeh M, Saadati N. Quick-MLCS: A new algorithm for the multiple longest common subsequence problem. In: Proceedings of the Fifth International C* Conference on Computer Science and Software Engineering; 2012:61–66.
15. Rudan I, Sidhu S, Papana A, Meng S, Xin–Wei Y, Wang W et al. Prevalence of rheumatoid arthritis in low–and middle–income countries: a systematic review and analysis. J Glob Health 2015; 5(1).
16. Skeoch S, Bruce I. Atherosclerosis in rheumatoid arthritis: is it all about inflammation. Nat Rev Rheumatol 2015; 11(7):390–400.
17. Saadati N, Moosavi M. Evaluation of heart dysfunction in patients with rheumatoid arthritis. Rheumatology Research Journal 2018; 3(3):101–106.
18. Skeoch E, Gabriel S. Overview of rheumatoid arthritis and mortality in relation to cardiovascular disease, in Handbook of Cardiovascular Disease Management. In: Rheumatoid Arthritis. Springer International Publishing; 2017:1–17.
19. Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis-Relation with the duration of the disease. Int J Cardiol 2008; 127(3):410–412.
20. Keser G, Capar I, Aksu K, Inal V, Danaoğlu Z, Savas R et al. Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol 2004; 33(4):244–245.
21. Dawson J, Goodson N, Graham D, Lynch M. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 2000; 39(112):1320–1325.
22. Go Y, Dulgheru R, Sugimoto T, Marchetta S, Oury C, Lancellotti P. Exercise Doppler echocardiography for the diagnosis of pulmonary hypertension: renewed interest and evolving roles. J Thorac Dis 2017; 9(9):2856–2861.
23. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Ollier W et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004; 33(4):231–238.
24. Pincus T, Callahan L. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol1986 13AD; 5(841–845).
25. Corrao S, Argano C, Pistone G, Messina S, Calvo L, Perticone F. Rheumatoid arthritis affects left ventricular mass: Systematic review and meta-analysis. Eur J Intern Med 2015; 26(4):259–267.
26. Mokotedi L, Gunter S, Robinson C, Norton G, Woodiwiss A, Tsang L et al. The Impact of Different Classification Criteria Sets on the Estimated Prevalence and Associated Risk Factors of Diastolic Dysfunction in Rheumatoid Arthritis. Int J Rheumatol 2017.
27. Millen A, Mokotedi L, Gunter S, Robinson C, Michel F, Woodiwiss A et al. SAT0124 Aortic stiffness and time to wave reflection are associated with left ventricular diastolic dysfunction measures in rheumatoid arthritis. BMJ Publishing Group Ltd 2018; 18.
28. Saadati N, Rajabian R. The effect of bisphosphonate on prevention of glucocorticoid-induced osteoporosis. Iranian red crescent medical Journal 2008; 10(1):8–11.
29. Assous N, Touzé E, Meune C, Kahan A, Allanore Y. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Jt Bone Spine Rev Rhum 2007; 74(1):66–72.
Files | ||
Issue | Vol 58, No 11 (2020) | |
Section | Original Article(s) | |
DOI | https://doi.org/10.18502/acta.v58i11.5143 | |
Keywords | ||
Cardiovascular morbidity Left ventricular diastolic dysfunction Rheumatoid arthritis Pulmonary hypertension Echocardiography |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |